Junshi Biosciences Announces the Phase 3 Study of JS005 (IL-17A) for the Treatment of Moderate to Severe Plaque Psoriasis Met Primary Endpoints
SHANGHAI, Sept. 07, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd…
Alnylam to Advance Zilebesiran into Global Phase 3 Cardiovascular Outcomes Trial
- Phase 3 Trial Informed by KARDIA-3 Phase 2 Study Results Presented…
Cytokinetics Announces Primary Results from MAPLE-HCM Presented at the European Society of Cardiology Congress 2025 and Published in The New England Journal Of Medicine
Positive Trial Demonstrates Superiority of Aficamten to Standard-of-Care Beta-Blocker Metoprolol Primary Endpoint…
Global Active Cyber Insurance Leader Coalition Launches in France
With Capacity Provided by Allianz, Active Insurance is Now Available to Businesses…
C2N Announces Major Global Expansion, Adds Six New International Partners
PrecivityAD2™ blood test now available in over seven additional countries with primary…
Successful Completion of First CRS with HIPEC on a 60-year-old Woman with Advanced Peritoneal Carcinomatosis
KOLKATA, India, July 28, 2025 /PRNewswire/ -- In a landmark achievement, a…
FDA Approves Apellis EMPAVELI (pegcetacoplan) as the First C3G and Primary IC-MPGN Treatment for Patients 12 and Older
Proven efficacy across all three key markers of disease—68% reduction in proteinuria,…
MSP Recovery Law Firm Secures Major Legal Win for MSP Recovery as Maryland Supreme Court Upholds Validity of Medicare Recovery Assignments for MSP Recovery and Its Healthcare Clients, Paving the Way for Medicare Recovery Rights Being Pursued Against GEICO
MIAMI, July 12, 2025 (GLOBE NEWSWIRE) -- MSP Recovery Law Firm, counsel…
Game-Changing HSA Reforms Just PassedHeres What It Means for Healthcare
Landmark legislation enables HSA use with Bronze/Catastrophic ACA plans, telehealth, and Direct…
IDEX Biometrics ASA: Mandatory notification of trades – 19 June 2025
Reference is made to the stock exchange notice from IDEX Biometrics ASA…